Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma, Inc. develops therapeutics for Alzheimer's disease and metabolic disorders as a clinical-stage biotechnology company. News about IGC Pharma commonly centers on IGC-AD1, its cannabinoid-based lead asset in the CALMA Phase 2 trial for agitation in Alzheimer's dementia, along with pipeline programs such as TGR-63, IGC-1C and IGC-M3 targeting amyloid plaques, tau pathways, neuroinflammation and related neurodegeneration biology.
Company updates also cover the use of artificial intelligence in drug discovery and clinical-trial operations, including the Agentic Harmonization Assistant platform for biomedical data harmonization. Other recurring developments include clinical-site expansion, caregiver and patient-engagement initiatives, psilocybin research authorization in Colombia, patent activity and financial reporting.
India Globalization Capital (IGC) announced a no objection letter from Health Canada for its Phase 2 trial of IGC-AD1, targeting agitation in Alzheimer's disease. This approval allows the company to proceed with trials at multiple sites, including Canada and the U.S. CEO Ram Mukunda emphasized the importance of this milestone for patient enrollment and FDA approval. The formulation utilizes low doses of THC and has shown promise in early trials. Approximately 15 million people in North America and Europe are affected by Alzheimer's, highlighting the potential market impact.
India Globalization Capital, Inc. (IGC) has filed a life sciences presentation with the SEC on Form 8K, detailing its initiatives, particularly focusing on low-dose THC drug formulations and cannabinoid-based consumer products.
IGC's leading drug candidate, IGC-AD1, is in Phase 2 trials, targeting agitation in Alzheimer’s dementia. The company also offers CBD products for various health needs. Despite these advancements, the press release includes forward-looking statements subject to risks, such as regulatory challenges and market conditions that could impact product commercialization.
India Globalization Capital, Inc. (NYSE: IGC) has expressed strong support for the Medical Marijuana and Cannabidiol Research Expansion Act, signed into law by President Biden on December 2, 2022. This Act aims to streamline research on marijuana and enhance product availability for medical applications. CEO Ram Mukunda noted that this development is crucial for advancing cannabis research. The company's IGC-AD1 is currently undergoing a Phase 2 clinical trial for Alzheimer’s-related agitation, following promising Phase 1 results showing potential benefits in managing Aβ plaques.
India Globalization Capital, Inc. (IGC) has initiated a Phase 2 clinical trial for IGC-AD1, aimed at treating agitation in Alzheimer's patients. The multi-center, double-blind study will enroll 146 participants, with the aim of assessing the treatment's safety and efficacy. The trial will take place across multiple sites in the U.S., Canada, and potentially South America, targeting diverse populations. IGC-AD1 is notable for being the first low-dose natural THC-based formulation in FDA trials for this condition. The trial's findings could provide insights into treating a condition affecting millions globally.
India Globalization Capital (NYSE American: IGC) announced that CEO Ram Mukunda will present at the RHK Disruptive Growth Conference in New York City on December 5 at 11:20 am ET. One-on-one meetings are scheduled for December 5 and 6. IGC focuses on developing cannabinoid-based formulations for treating diseases, including Alzheimer's and Parkinson's, with its leading candidate IGC-AD1 recently entering Phase 2 clinical trials. The company also offers CBD-based consumer products like Holief and Sunday Seltzer, catering to various health needs.
India Globalization Capital (NYSE American: IGC) announced its second fiscal quarter 2023 financial results, highlighting significant progress in its investigational drugs for Alzheimer’s. IGC-AD1 is entering Phase 2 trials aimed at treating agitation in Alzheimer’s dementia, with a primary endpoint assessed over six weeks. The company's revenue surged to approximately $202,000, up from $56,000 a year earlier, largely due to increased sales of CBD products. SG&A expenses dropped to $1.9 million, while R&D expenses rose to $768,000, reflecting ongoing trials. The net loss decreased to $2.4 million or ($0.05) per share.
India Globalization Capital (IGC) announced that the USPTO has granted a second patent (#11,446,276) for treating Alzheimer’s disease with extreme low dose THC. The original application was initiated by the University of South Florida in 2015, and IGC has developed IGC-AD1 based on this research. Early testing indicates IGC-AD1 may alleviate key Alzheimer’s symptoms, prompting a Phase 2 protocol filing with the FDA for further efficacy testing. Currently, no pharmacological treatments for agitation in Alzheimer’s patients exist, presenting a significant market opportunity for IGC.
India Globalization Capital (IGC) held its Annual Meeting of Stockholders on September 9, 2022, where all proposals were approved. Key decisions included the election of Ram Mukunda and Congressman James Moran as Class C directors until 2025, and Claudia Grimaldi as a Class A director until 2023. Additionally, Manohar Chowdhry & Associates was ratified as the independent accounting firm for the 2023 fiscal year. The Board granted 3,000,000 shares of common stock to employees and advisors based on performance metrics.
India Globalization Capital (IGC) reported its financial results for Q1 2023 ended June 30, 2022. Revenue increased to approximately $212,000 from $77,000 in Q1 2022. The company has submitted a Phase 2 clinical trial protocol to the FDA for IGC-AD1 aimed at treating agitation in Alzheimer's patients. R&D expenses rose significantly to $1.4 million, a 214% increase due to the trial progress. However, a net loss of $2.8 million, or ($0.05) per share, was recorded, up from a net loss of $1.8 million or ($0.04) per share in the previous year.
India Globalization Capital (IGC) reported its financial results for Fiscal Year 2022, revealing revenues of approximately $397,000, down from $898,000 in Fiscal 2021. Despite a 48% gross margin improvement, driven by higher margin product sales, SG&A expenses surged 68% to $13.2 million due to one-time costs, increasing the net loss to about $15 million or $0.30 per share. The company successfully completed a Phase 1 trial for IGC-AD1 targeting Alzheimer’s symptoms and plans further studies on both IGC-AD1 and TGR-63, a promising Alzheimer's treatment.